Impact of preprocedural anemia on in-hospital and follow-up outcomes of chronic total occlusion percutaneous coronary intervention.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
11 2023
Historique:
revised: 17 07 2023
received: 11 05 2023
accepted: 15 08 2023
medline: 15 11 2023
pubmed: 8 9 2023
entrez: 8 9 2023
Statut: ppublish

Résumé

The impact of preprocedural anemia on the outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has received limited study. We examined the clinical and angiographic characteristics and procedural outcomes of 8633 CTO PCIs performed at 39 US and non-US centers between 2012 and 2023. Anemia was defined as a hemoglobin level of <13 g/dL in men and <12 g/dL in women. Anemia was present in 1652 (19%) patients undergoing CTO PCI. Anemic patients had a higher incidence of comorbidities, such as diabetes mellitus, hypertension, dyslipidemia, heart failure, cerebrovascular disease, and peripheral arterial disease. CTOs in anemic patients were more likely to have complex angiographic characteristics, including smaller diameter, longer length, moderate to severe calcification, and moderate to severe proximal tortuosity. Anemic patients required longer procedure (119 vs. 107 min; p < 0.001) and fluoroscopy (45 vs. 40 min; p < 0.001) times but received similar contrast volumes. Technical success was similar between the two groups. In-hospital major adverse cardiac events (MACE) rates were higher in patients with anemia; however, this association was no longer significant after adjusting for confounding factors. Baseline anemia was independently associated with follow-up MACE (adjusted hazard ratio [HR]: 1.63; 95% confidence interval [CI]: 1.07-2.49; p = 0.023) and all-cause mortality (adjusted HR: 3.03; 95% CI: 1.41-6.49; p = 0.004). Preprocedural anemia is associated with more comorbidities, higher lesion complexity, longer procedure times, and higher follow-up MACE and mortality after CTO PCI.

Sections du résumé

BACKGROUND
The impact of preprocedural anemia on the outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has received limited study.
METHODS
We examined the clinical and angiographic characteristics and procedural outcomes of 8633 CTO PCIs performed at 39 US and non-US centers between 2012 and 2023. Anemia was defined as a hemoglobin level of <13 g/dL in men and <12 g/dL in women.
RESULTS
Anemia was present in 1652 (19%) patients undergoing CTO PCI. Anemic patients had a higher incidence of comorbidities, such as diabetes mellitus, hypertension, dyslipidemia, heart failure, cerebrovascular disease, and peripheral arterial disease. CTOs in anemic patients were more likely to have complex angiographic characteristics, including smaller diameter, longer length, moderate to severe calcification, and moderate to severe proximal tortuosity. Anemic patients required longer procedure (119 vs. 107 min; p < 0.001) and fluoroscopy (45 vs. 40 min; p < 0.001) times but received similar contrast volumes. Technical success was similar between the two groups. In-hospital major adverse cardiac events (MACE) rates were higher in patients with anemia; however, this association was no longer significant after adjusting for confounding factors. Baseline anemia was independently associated with follow-up MACE (adjusted hazard ratio [HR]: 1.63; 95% confidence interval [CI]: 1.07-2.49; p = 0.023) and all-cause mortality (adjusted HR: 3.03; 95% CI: 1.41-6.49; p = 0.004).
CONCLUSIONS
Preprocedural anemia is associated with more comorbidities, higher lesion complexity, longer procedure times, and higher follow-up MACE and mortality after CTO PCI.

Identifiants

pubmed: 37681964
doi: 10.1002/ccd.30810
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

857-863

Subventions

Organisme : The authors are grateful for the philanthropic support of our generous anonymous donors, and the philanthropic support of Drs. Mary Ann and Donald A Sens; Mrs. Diane and Dr. Cline Hickok; Mrs. Wilma and Mr. Dale Johnson; Mrs. Charlotte and Mr. Jerry Golinvaux Family Fund; the Roehl Family Foundation; the Joseph Durda Foundation. The generous gifts of these donors to the Minneapolis Heart Institute Foundation's Science Center for Coronary Artery Disease (CCAD) helped support this research proje

Informations de copyright

© 2023 Wiley Periodicals LLC.

Références

Nikolsky E, Aymong ED, Halkin A, et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol. 2004;44(3):547-553. doi:10.1016/j.jacc.2004.03.080
Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111(16):2042-2049. doi:10.1161/01.Cir.0000162477.70955.5f
Kunadian V, Mehran R, Lincoff AM, et al. Effect of anemia on frequency of short- and long-term clinical events in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). Am J Cardiol. 2014;114(12):1823-1829. doi:10.1016/j.amjcard.2014.09.023
Al-Hijji MA, Gulati R, Lennon RJ, et al. Outcomes of percutaneous coronary interventions in patients with anemia presenting with acute coronary syndrome. Mayo Clin Proc. 2018;93(10):1448-1461. doi:10.1016/j.mayocp.2018.03.030
Hussein A, Awad MS, Sabra AM, Mahmoud HEM. Anemia is a novel predictor for clinical ISR following PCI. Egypt Heart J. 2021;73(1):40. doi:10.1186/s43044-021-00163-8
Kitai Y, Ozasa N, Morimoto T, et al. Prognostic implications of anemia with or without chronic kidney disease in patients undergoing elective percutaneous coronary intervention. Int J Cardiol. 2013;168(6):5221-5228. doi:10.1016/j.ijcard.2013.08.029
Hosseini SK, Ansari MJA, Lotfi Tokaldany M, Sharafi A, Hakki Kazazi E, Poorhosseini H. Association between preprocedural hemoglobin level and 1-year outcome of elective percutaneous coronary intervention. J Cardiovasc Med. 2014;15(4):331-333. doi:10.2459/JCM.0b013e32835ec938
Stähli BE, Gebhard C, Gick M, et al. Impact of anemia on long-term outcomes after percutaneous coronary intervention for chronic total occlusion. Catheter Cardiovasc Interv. 2018;91(2):226-233. doi:10.1002/ccd.27412
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208. doi:10.1016/j.jbi.2019.103208
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010
W.H.O. Scientific Group on Nutritional Anaemias. Nutritional anaemias: report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405:5-37.
Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020-2035. doi:10.1161/CIR.0b013e31826e1058
Morino Y, Abe M, Morimoto T, et al. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes. JACC Cardiovasc Interv. 2011;4(2):213-221. doi:10.1016/j.jcin.2010.09.024
Christopoulos G, Kandzari DE, Yeh RW, et al. Development and validation of a novel scoring system for predicting technical success of chronic total occlusion percutaneous coronary interventions. JACC Cardiovasc Interv. 2016;9(1):1-9. doi:10.1016/j.jcin.2015.09.022
Simsek B, Kostantinis S, Karacsonyi J, et al. Predicting periprocedural complications in chronic total occlusion percutaneous coronary intervention. JACC Cardiovasc Interv. 2022;15(14):1413-1422. doi:10.1016/j.jcin.2022.06.007
Kostantinis S, Simsek B, Karacsonyi J, et al. Development and validation of a scoring system for predicting clinical coronary artery perforation during percutaneous coronary intervention of chronic total occlusions: the PROGRESS-CTO perforation score. EuroIntervention. 2022;18(12):1022-1030. doi:10.4244/eij-d-22-00593
Le CHH. The prevalence of anemia and moderate-severe anemia in the US population (NHANES 2003-2012). PLoS One. 2016;11(11):e0166635. doi:10.1371/journal.pone.0166635
Thomas MC, Tsalamandris C, MacIsaac RJ, Jerums G. The epidemiology of hemoglobin levels in patients with type 2 diabetes. Am J Kidney Dis. 2006;48(4):537-545. doi:10.1053/j.ajkd.2006.06.011
Esteban C, Hernández-Rodríguez I. Peripheral arterial disease and anaemia. Med Clín. 2022;158(5):221-228. doi:10.1016/j.medcle.2021.07.012
Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017;18(1):345. doi:10.1186/s12882-017-0688-1
Nikolakopoulos I, Choi JW, Khatri JJ, et al. Follow-up outcomes after chronic total occlusion percutaneous coronary intervention in patients with and without prior coronary artery bypass graft surgery: insights from the PROGRESS-CTO Registry. J Invasive Cardiol. 2020;32(8):315-320.
Xenogiannis I, Gkargkoulas F, Karmpaliotis D, et al. The impact of peripheral artery disease in chronic total occlusion percutaneous coronary intervention (insights from PROGRESS-CTO Registry). Angiology. 2020;71(3):274-280. doi:10.1177/0003319719895178
McKechnie RS, Smith D, Montoye C, et al. Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation. 2004;110(3):271-277. doi:10.1161/01.CIR.0000134964.01697.C7
Li W, Li D, Han F, Xu T, Zhang Y, Zhu H. Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions. Int Urol Nephrol. 2013;45(4):1065-1070. doi:10.1007/s11255-012-0340-8
Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int. 2005;67(2):706-713. doi:10.1111/j.1523-1755.2005.67131.x
Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95(1):13-19. doi:10.1016/j.amjcard.2004.08.056
Werner GS, Lorenz S, Yaginuma K, et al. A prospective study on the incidence of contrast-associated acute kidney injury after recanalization of chronic total coronary occlusions with contemporary interventional techniques. Int J Cardiol. 2021;337:38-43. doi:10.1016/j.ijcard.2021.05.030

Auteurs

Athanasios Rempakos (A)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Spyridon Kostantinis (S)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Bahadir Simsek (B)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Judit Karacsonyi (J)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Michaella Alexandrou (M)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

James W Choi (JW)

Texas Health Presbyterian Hospital, Dallas, Texas, USA.

Paul Poommipanit (P)

University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA.

Jaikirshan J Khatri (JJ)

Cleveland Clinic, Cleveland, Ohio, USA.

Laura Young (L)

Cleveland Clinic, Cleveland, Ohio, USA.

Rhian Davies (R)

WellSpan York Hospital, York, Pennsylvania, USA.

Stewart Benton (S)

WellSpan York Hospital, York, Pennsylvania, USA.

Farouc A Jaffer (FA)

Massachusetts General Hospital, Boston, Massachusetts, USA.

Raj Chandwaney (R)

Oklahoma Heart Institute, Tulsa, Oklahoma, USA.

Lorenzo Azzalini (L)

Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington, USA.

Khaldoon Alaswad (K)

Henry Ford Cardiovascular Division, Detroit, Michigan, USA.

Brian Jefferson (B)

Tristar Centennial Medical Center, Nashville, Tennessee, USA.

Jarrod Frizzell (J)

St. Vincent Hospital, Indianapolis, Indiana, USA.

Nidal Abi-Rafeh (N)

North Oaks Health System, Hammond, Louisiana, USA.

Ahmed Elguindy (A)

Aswan Heart Center, Magdi Yacoub Foundation, Cairo, Egypt.

Omer Goktekin (O)

Memorial Bahcelievler Hospital, Istanbul, Turkey.

Bavana V Rangan (BV)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Olga C Mastrodemos (OC)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Salman S Allana (SS)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Yader Sandoval (Y)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Nicholas M Burke (NM)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Emmanouil S Brilakis (ES)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Sevket Gorgulu (S)

Biruni University Medical School, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH